NCT06658951招募中不适用
Exploratory Study to Evaluate the Safety and Preliminary Efficacy of Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Identification of Maximum Tolerated Dose (MTD) & Incidence of Dose-limiting Toxicities (DLTs)
研究概览
简要总结
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors.
详细描述
All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.The dose escalation phase will determine the maximum tolerated dose (MTD) of Anti-HER2 CAR-T cell injection. Additional patients will be enrolled in the dose expansion phase to further characterize the safety profile and evaluate the efficacy of Anti-HER2 CAR-T cell injection, and establish recommended phase 2 dose (RP2D).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. 18 to 70 years old (including cut-off value), gender is not limited.
- •2. Solid tumors that histological diagnosis of malignancy refractory to, or relapsing after standard therapy, including but not limited to gastric cancer, biliary system tumors, bladder cancer, ovarian cancer, endometrial cancer, cervical cancer, colorectal cancer, breast cancer, lung cancer, esophageal cancer, etc.
- •3. At least one measurable lesion according to RECIST v1.
- •4. HER2 should be positive confirmed by Immunohistochemistry in tumor tissue samples.
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •6. Life expectancy ≥ 3 months.
- •7. The organ function must meet the protocol requirements.
- •8. Female participants of childbearing potential must undergo a pregnancy test and the results must be negative. Female participants of childbearing potential or male participants whose sex partner has childbearing potential must be willing to use effective methods of contraception from screening period to at least 1 year after infusion.
- •9. Participants must be able to understand the protocol and be willing to enroll the study, sign the informed consent, and be able to comply with the study and follow-up procedures.
排除标准
- •1. Pregnant or lactating women.
- •2. Patients with hepatitis B surface antigen (HBsAg) positive. Patients who is hepatitis B core antibody (HBcAb) positive and the quantification of HBV DNA in peripheral blood is higher than the lower limit of detection. Patients who is hepatitis C virus (HCV) antibody positive and quantification of HCV DNA in peripheral blood is higher than the lower limit of detection. Patients with human immunodeficiency virus (HIV) antibody positive, or syphilis antibody positive.
- •3. The toxicities caused by the prior therapy (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.) have not recovered to grade 1 according to CTCAE, except for hair loss and peripheral sensory nerve disorders.
- •4. Have received any allogeneic tissue/organ transplantation (including bone marrow transplantation, stem cell transplantation, liver transplantation, kidney transplantation), except for the transplantation that does not require immunosuppressive therapy (such as: corneal transplantation, hair transplantation.)
- •5. Patients have received anti-HER2 CAR-T cell therapy.
- •6. Patients who have history of major surgery and unrecovered severe trauma within 4 weeks prior to signing informed consent; or plan to have major surgery within 12 weeks of cell therapy.
- •7. Presence of known central nervous system metastases, but the following patients will be allowed: a) Asymptomatic brain metastases; b) Clinically stable (no radiographic progression within 4 weeks before apheresis and return of any neurologic symptoms to baseline), and with no need for corticosteroids or other treatment for brain metastases for ≥ 4 weeks.
- •8. Patients with clinically significant systemic disease (such as: severe active infection or significant cardiac, pulmonary, hepatic, nervous system, or other organ dysfunction) that evaluated by the investigator would impair the patients' ability to tolerate the treatments used in this study or significantly increase the risk of complications.
- •9. History of severe systemic hypersensitivity reaction to the drugs/ingredients [fludarabine, cyclophosphamide, dimethyl sulfoxide (DMSO), low molecular dextran, human serum albumin (HSA), etc.] used in this study.
- •10. Patients have received attenuated vaccine within 4 weeks prior to signing informed consent.
- •11. Patients have received other clinical trials within 4 weeks prior to signing informed consent.
- •12. History of another malignancy tumor within the previous five years, except for adequately treated non-melanoma skin cancer, carcinoma in situ of bladder, stomach, colon, cervix/dysplasia, melanoma, or breast.
- •13. History of neuropsychiatric diseases diagnosed by the ICD-11 criteria or evaluated by investigator, including but not limited to epilepsy, schizophrenia, dementia, drug and alcohol addictions.
- •14. For any other reasons, the patients are believed not suitable for participation in this study by investigators.
研究组 & 干预措施
Anti-HER2 CAR-T cells
Experimental
All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
干预措施: Anti-HER2 CAR-T cells (Biological)
结局指标
主要结局
Identification of Maximum Tolerated Dose (MTD) & Incidence of Dose-limiting Toxicities (DLTs)
时间窗: 4 weeks after the CAR-T cells infusion
Incidence and severity of dose-limiting toxicities (DLTs) following infusion of CAR-T cell injection, at each dose level tested in dose escalation phase.
Adverse Events (AEs)
时间窗: 2 years
Incidence and severity of adverse events.
次要结局
- Objective Response Rate (ORR)(2 years)
- Disease Control Rate (DCR)(2 years)
- Progression-Free Survival (PFS)(2 years)
- Overall Survival (OS)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid TumorsCDH17-positive Advanced Malignant Solid TumorsNCT06501183Shanghai Pudong Hospital17
已完成
1 期
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLNCT05548088Peking University People's Hospital11
招募中
1 期
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05913804Institute of Hematology & Blood Diseases Hospital, China12
已完成
1 期
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaNCT05518357Hebei Yanda Ludaopei Hospital2
已完成
不适用
LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaAcute Myelogenous LeukemiaChronic Myelomonocytic LeukemiaNCT05739409Institute of Hematology & Blood Diseases Hospital, China1